NEW YORK, NY / ACCESSWIRE / May 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Amdocs Limited (NASDAQ:DOX)
Class Period: December 13, 2016 - March 30, 2021
Lead Plaintiff Deadline: June 8, 2021
The complaint alleges that throughout the class period Amdocs Limited made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in DOX: http://www.kleinstocklaw.com/pslra-1/amdocs-limited-loss-submission-form?id=15464&from=1
Canaan Inc. (NASDAQ:CAN)
Class Period: February 10, 2021 - April 9, 2021
Lead Plaintiff Deadline: June 14, 2021
According to the complaint, Canaan Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company's next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan's 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 ("4Q19") sales and more than 93% quarter-over-quarter compared to its third quarter FY20 ("3Q20") sales.
Learn about your recoverable losses in CAN: http://www.kleinstocklaw.com/pslra-1/canaan-inc-loss-submission-form-2?id=15464&from=1
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
Class Period: June 15, 2020 - April 4, 2021
Lead Plaintiff Deadline: June 18, 2021
The ACAD lawsuit alleges Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in ACAD: http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=15464&from=1
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
SOURCE: The Klein Law Firm
View source version on accesswire.com: